lirucitinib is a JAK inhibitor, and has antiinflammatory activity. lirucitinib inhibits various itch- and inflammation-inducing cytokines that depend on JAK1 enzyme activity, as well as allergy-related cytokines. lirucitinib can be used for the study of pruritic skin diseases [1]
In Vitro, Lirucitinib exerts its therapeutic effect by selectively inhibiting JAK1. By blocking the activity of JAK1, Lirucitinib disrupts the downstream signaling of various pro-inflammatory and pruritogenic (itch-inducing) cytokines that are dependent on this enzyme.
References:
[1]. WHO Drug Information, Vol. 38, No. 4, 2024.
In Vitro, Lirucitinib exerts its therapeutic effect by selectively inhibiting JAK1. By blocking the activity of JAK1, Lirucitinib disrupts the downstream signaling of various pro-inflammatory and pruritogenic (itch-inducing) cytokines that are dependent on this enzyme.
References:
[1]. WHO Drug Information, Vol. 38, No. 4, 2024.